GF Fund Management Boosts Amgen Stake by 4.8%

Institutional investor increases holdings in biotech giant to $44 million

Apr. 18, 2026 at 8:57am

Got story updates? Submit your updates here. ›

An extreme close-up of precision biotech machinery and equipment, dramatically lit against a dark background, conceptually representing the complex financial and technological infrastructure powering Amgen's drug development and manufacturing.Amgen's robust biotech infrastructure powers its pipeline of innovative treatments, attracting continued investment from institutional funds.Thousand Oaks Today

GF Fund Management CO. LTD., an institutional investor, increased its stake in Amgen Inc. (NASDAQ:AMGN) by 4.8% in the fourth quarter, according to a recent SEC filing. The fund now owns 134,415 shares of the medical research company's stock, valued at approximately $44 million.

Why it matters

Amgen is a leading global biotechnology company focused on developing innovative human therapeutics. Institutional investors closely monitor and adjust their positions in Amgen as the company navigates the competitive biopharmaceutical landscape and works to bring new treatments to market.

The details

According to the filing, GF Fund Management purchased an additional 6,216 shares of Amgen during the fourth quarter, bringing its total position to 134,415 shares. Amgen comprises 0.8% of GF Fund Management's investment portfolio, making it the firm's 27th largest holding. The move comes as Amgen continues to invest in its pipeline of biologics and work to expand its commercial product portfolio.

  • GF Fund Management filed the disclosure with the SEC on April 18, 2026.
  • The stake increase occurred during the fourth quarter of 2025.

The players

GF Fund Management CO. LTD.

An institutional investment firm that owns a $44 million stake in Amgen Inc.

Amgen Inc.

A global biotechnology company focused on developing innovative human therapeutics.

Got photos? Submit your photos here. ›

What’s next

Investors will likely continue to monitor Amgen's financial performance and pipeline progress as the company navigates the competitive biopharmaceutical landscape.

The takeaway

This filing highlights the ongoing interest from institutional investors in Amgen, a leading biotech firm with a diverse portfolio of innovative treatments. The 4.8% stake increase by GF Fund Management underscores the company's potential for long-term growth.